ICONIQ Growth
hybrid fundWebsite
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Evidence [2] shows ICONIQ Growth led a $60 million Series B in Causaly, an AI platform for biomedical research. That is a close fit to OpenDrugs' AI-native biomedical evidence and discovery workspace, making it a credible venture capital target for a proof-of-concept science data platform.